Co-Author
This page shows the publications co-authored by David Avigan and Kenneth Anderson.
Connection Strength
1.182
-
Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
Score: 0.174
-
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
Score: 0.135
-
Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49.
Score: 0.126
-
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
Score: 0.113
-
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
Score: 0.109
-
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
Score: 0.105
-
Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005 Jun; 129(5):687-700.
Score: 0.077
-
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
Score: 0.072
-
Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. Oncotarget. 2017 Sep 19; 8(41):69237-69249.
Score: 0.045
-
MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017 09; 178(6):914-926.
Score: 0.045
-
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90.
Score: 0.043
-
MUC1-C drives MYC in multiple myeloma. Blood. 2016 05 26; 127(21):2587-97.
Score: 0.041
-
Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
Score: 0.030
-
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
Score: 0.027
-
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
Score: 0.026
-
Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002 Apr 01; 99(7):2512-7.
Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.